NASDAQ:PULM Pulmatrix (PULM) Stock Forecast, Price & News $2.12 -0.05 (-2.30%) (As of 02:40 PM ET) Add Compare Share Share Today's Range$2.10▼$2.1550-Day Range$2.16▼$2.7052-Week Range$2.10▼$4.49Volume4,920 shsAverage Volume22,160 shsMarket Capitalization$7.74 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Pulmatrix MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside373.9% Upside$10.00 Price TargetShort InterestHealthy0.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.54Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($4.38) to ($4.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPulmatrix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Pulmatrix has a forecasted upside of 373.9% from its current price of $2.11.Amount of Analyst CoveragePulmatrix has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.07% of the float of Pulmatrix has been sold short.Short Interest Ratio / Days to CoverPulmatrix has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulmatrix has recently decreased by 20.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPulmatrix does not currently pay a dividend.Dividend GrowthPulmatrix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PULM. Previous Next 2.0 News and Social Media Coverage News SentimentPulmatrix has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Pulmatrix this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Pulmatrix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pulmatrix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.61% of the stock of Pulmatrix is held by insiders.Percentage Held by InstitutionsOnly 11.62% of the stock of Pulmatrix is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Pulmatrix are expected to decrease in the coming year, from ($4.38) to ($4.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmatrix is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmatrix is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmatrix has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pulmatrix (NASDAQ:PULM) StockPulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.Read More PULM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PULM Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Pulmatrix (NASDAQ:PULM)September 19, 2023 | markets.businessinsider.comPulmatrix Receives Study May Proceed Letter From FDA For Phase 2 Study To Evaluate PUR3100September 25, 2023 | Behind the Markets (Ad)6.5 Million Americans Are DESPERATE for This New Drug from One Tiny CompanyDecades of pent-up demand for this "first-ever" treatment could give you WINDFALL PROFITS... Click here to learn more >>>September 19, 2023 | finance.yahoo.comPulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute MigraineSeptember 15, 2023 | americanbankingnews.comPulmatrix (NASDAQ:PULM) Research Coverage Started at StockNews.comSeptember 11, 2023 | msn.comPulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock NowAugust 23, 2023 | finance.yahoo.comPulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled ItraconazoleAugust 10, 2023 | finanznachrichten.dePulmatrix, Inc.: Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateSeptember 25, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 10, 2023 | msn.comPulmatrix GAAP EPS of -$1.04, revenue of $1.84MAugust 10, 2023 | finance.yahoo.comPulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 11, 2023 | finance.yahoo.comPulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute MigraineJune 15, 2023 | finance.yahoo.comPulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache SocietyMay 24, 2023 | finance.yahoo.comPulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International ConventionMay 15, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Pulmatrix (PULM)May 12, 2023 | msn.comPulmatrix GAAP EPS of -$1.22, revenue of $1.5MMay 12, 2023 | finance.yahoo.comPulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate UpdateMay 9, 2023 | marketwatch.comInjectable Drug Delivery Technology Market: Latest Innovations, Drivers and Industry Key Events 2023-2031May 2, 2023 | finance.yahoo.comPulmatrix Supports World Asthma Day 2023April 20, 2023 | sg.finance.yahoo.comPulmatrix, Inc. (PULM) stock historical prices & data – Yahoo FinanceMarch 30, 2023 | finance.yahoo.comPulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate UpdateFebruary 27, 2023 | marketwatch.comInjectable Drug Delivery Devices Market is Booming by Size, Revenue, Trend and Top Growing Companies 2023-2028February 18, 2023 | marketwatch.comGlobal Targeted Drug Delivery System Market 2023 Global Share, Key Country Analysis and Forecasts 2030 By VMReportsFebruary 6, 2023 | finance.yahoo.comPulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with AsthmaJanuary 25, 2023 | finance.yahoo.comPulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"December 17, 2022 | finance.yahoo.comPulmatrix, Inc. (PULM) Stock Historical Prices & Data - Yahoo FinanceNovember 10, 2022 | finance.yahoo.comPulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateSee More Headlines Receive PULM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter. Email Address PULM Company Calendar Last Earnings8/10/2023Today9/25/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PULM CUSIPN/A CIK1574235 Webwww.pulmatrix.com Phone(781) 357-2333Fax707-525-9906Employees28Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+360.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,840,000.00 Net Margins-253.24% Pretax Margin-253.24% Return on Equity-60.14% Return on Assets-45.29% Debt Debt-to-Equity RatioN/A Current Ratio7.61 Quick Ratio7.61 Sales & Book Value Annual Sales$6.07 million Price / Sales1.30 Cash FlowN/A Price / Cash FlowN/A Book Value$8.55 per share Price / Book0.25Miscellaneous Outstanding Shares3,650,000Free Float3,520,000Market Cap$7.92 million OptionableOptionable Beta0.75 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Teofilo David Raad MBA (Age 53)Pres, CEO & Director Comp: $772.7kMr. Peter Ludlum CMA (Age 68)MBA, Interim CFO and Principal Accounting & Financial Officer Comp: $398.58kDr. Margaret M. Wasilewski M.D. (Age 66)Chief Medical Officer Comp: $585.84kDr. Alexander M. Klibanov Ph.D. (Age 73)Founder Key CompetitorsProtagenic TherapeuticsNASDAQ:PTIXCohBarNASDAQ:CWBRApplied Molecular TransportNASDAQ:AMTIGalera TherapeuticsNASDAQ:GRTXXenetic BiosciencesNASDAQ:XBIOView All Competitors PULM Stock - Frequently Asked Questions Should I buy or sell Pulmatrix stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PULM shares. View PULM analyst ratings or view top-rated stocks. What is Pulmatrix's stock price forecast for 2023? 1 analysts have issued 1-year price objectives for Pulmatrix's shares. Their PULM share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 360.8% from the stock's current price. View analysts price targets for PULM or view top-rated stocks among Wall Street analysts. How have PULM shares performed in 2023? Pulmatrix's stock was trading at $3.88 at the beginning of 2023. Since then, PULM shares have decreased by 44.1% and is now trading at $2.17. View the best growth stocks for 2023 here. Are investors shorting Pulmatrix? Pulmatrix saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 2,700 shares, a drop of 20.6% from the August 15th total of 3,400 shares. Based on an average trading volume of 12,900 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the company's shares are sold short. View Pulmatrix's Short Interest. When is Pulmatrix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our PULM earnings forecast. How were Pulmatrix's earnings last quarter? Pulmatrix, Inc. (NASDAQ:PULM) posted its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($1.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.23) by $0.19. The biotechnology company earned $1.84 million during the quarter, compared to the consensus estimate of $1.51 million. Pulmatrix had a negative trailing twelve-month return on equity of 60.14% and a negative net margin of 253.24%. When did Pulmatrix's stock split? Shares of Pulmatrix reverse split before market open on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Pulmatrix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK). What is Pulmatrix's stock symbol? Pulmatrix trades on the NASDAQ under the ticker symbol "PULM." How do I buy shares of Pulmatrix? Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pulmatrix's stock price today? One share of PULM stock can currently be purchased for approximately $2.17. How much money does Pulmatrix make? Pulmatrix (NASDAQ:PULM) has a market capitalization of $7.92 million and generates $6.07 million in revenue each year. The biotechnology company earns $-18,840,000.00 in net income (profit) each year or ($4.85) on an earnings per share basis. How can I contact Pulmatrix? Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The official website for the company is www.pulmatrix.com. The biotechnology company can be reached via phone at (781) 357-2333, via email at rclarke@pulmatrix.com, or via fax at 707-525-9906. This page (NASDAQ:PULM) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.